🔗 Visit the ClinicalTrials.gov page for NCT01051570
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2011 | 0.93 |
| 2 | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. | Int J Mol Sci | 2013 | 0.88 |
| 3 | Emerging molecularly targeted therapies in castration refractory prostate cancer. | Prostate Cancer | 2013 | 0.83 |
| 4 | Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. | Urology | 2015 | 0.81 |
| 5 | Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. | Clin Med Insights Oncol | 2016 | 0.80 |